Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

REGN5093-M114

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Regeneron

Drug class:

Tubulin inhibitor, c-MET-targeted antibody-drug conjugate

Related drugs:

›

MET expression	Non Small Cell Lung Cancer	MET expression	Non Small Cell Lung Cancer	REGN5093-M114 Sensitive: D – Preclinical REGN5093-M114 Sensitive : D	REGN5093-M114 Sensitive: D – Preclinical REGN5093-M114 Sensitive : D
EGFR mutation + PTEN deletion	Non Small Cell Lung Cancer	EGFR mutation + PTEN deletion	Non Small Cell Lung Cancer	osimertinib + savolitinib + REGN5093-M114 Sensitive: D – Preclinical osimertinib + savolitinib + REGN5093-M114 Sensitive : D	osimertinib + savolitinib + REGN5093-M114 Sensitive: D – Preclinical osimertinib + savolitinib + REGN5093-M114 Sensitive : D
MET Y1230C	Non Small Cell Lung Cancer	MET Y1230C	Non Small Cell Lung Cancer	osimertinib + savolitinib + REGN5093-M114 Sensitive: D – Preclinical osimertinib + savolitinib + REGN5093-M114 Sensitive : D	osimertinib + savolitinib + REGN5093-M114 Sensitive: D – Preclinical osimertinib + savolitinib + REGN5093-M114 Sensitive : D